Product Description
An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist GSK3745417 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-gsk3745417)
Mechanisms of Action: STING Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, France, Japan, Korea, Netherlands, Spain, United States, Unknown Location
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2031220077 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2024-07-17 |
|
NCT03843359 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2024-04-05 |